OOIR: Observatory of International Research

Papers

(The H4-Index of Multiple Sclerosis and Related Disorders is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Characteristics and predictors of sexual dysfunction in men with multiple sclerosis	84
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis	76
The clinical and radiological features and prevalence of Neuro-Behçet's Disease: A retrospective cohort multicenter study in Saudi Arabia	68
Functional electrical stimulation combined with voluntary cycling accentuates VO2 response in people with severe multiple sclerosis: A pilot study	65
OCT-Angiography in AQP4-positive NMOSD: finding subclinical disease using a new tool	65
Spatio-Temporal Gait Parameters to Distinguish Multiple Sclerosis Disability during Dual- Task Walk	60
Clinical outcomes of partial sensory root rhizotomy on patients with recurrence of multiple sclerosing trigeminal neuralgia after percutaneous balloon compression	59
Utilizing the ISway to Identify and Compare Balance Domain Deficits in People with Multiple Sclerosis	57
Inform Interferon Beta Exposure in the 2nd and 3rd Trimester of Pregnancy: A Register-Based Drug Utilisation Study in Finland and Sweden	49
The Effect of Seasonal Variation on Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis in Saudi Arabia	49
Challenges of MS Patients for Receiving Health Care Services	47
Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany	47
Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease	47
Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study	45
Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis	45
Effects of flexible scheduling and virtual visits on burnout for clinicians: 1- year follow-up	44
How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?	44
Infrequent patterns in cerebrospinal fluid isofocusing test: Clinical significance and contribution of IgG index and Reiber diagram to their interpretation	43
The presence of SARS-CoV2 antibodies in MS patients	42
Nordic clues for uncovering the aetiology of Multiple Sclerosis	41
Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders	39
Dosing schedules for Ofatumumab in multiple sclerosis: Overegging the pudding	39
Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis	39
Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis	38
Infection incidence and management in multiple sclerosis patients after initiating disease-modifying therapy	38

Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report	38
Utilizing metabolomic profiling as a supportive diagnostic tool for radiologically isolated syndrome	37
Body size perceptions & diet modification in youth with multiple sclerosis	37
Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?	36
Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies	36
Cerebrospinal fluid biomarkers as predictors of multiple sclerosis severity	36
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis	35
Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic	34
Advances in maintenance therapies for neuromyelitis optica spectrum disorders: A new era of targeted drugs	34